Research Highlight | Published:

KIDNEY CANCER

Checkpoint inhibitor combination sets the wheels IMmotion

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

    Original articles

    1. McDermott, D. F. et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat. Med. 24, 749–757 (2018)

    2. Motzer, R. J. et al. IMmotion151: a randomized phase III study of atezolizumab plus bevacizumab vs sunitinib in untreated metastatic renal cell carcinoma (mRCC) [abstract]. J Clin Oncol. 36, 578 (2018)

    Download references

    Author information

    Correspondence to Conor A. Bradley.

    Rights and permissions

    Reprints and Permissions

    About this article

    Verify currency and authenticity via CrossMark